Header Logo

Connection

Mark Pollack to Anti-Anxiety Agents

Back to Details
This is a "connection" page, showing publications Mark Pollack has written about Anti-Anxiety Agents.
Mark Pollack
Connection Strength
4.060
Anti-Anxiety Agents
  1. Response to Silberman. Am J Psychiatry. 2014 Jul; 171(7):795-6.
    View in: PubMed
    Score: 0.472
  2. A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder. Am J Psychiatry. 2014 Jan; 171(1):44-53.
    View in: PubMed
    Score: 0.456
  3. Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled trial. J Clin Psychiatry. 2010 May; 71(5):627-31.
    View in: PubMed
    Score: 0.345
  4. Refractory generalized anxiety disorder. J Clin Psychiatry. 2009; 70 Suppl 2:32-8.
    View in: PubMed
    Score: 0.323
  5. Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies. J Clin Psychopharmacol. 2008 Jun; 28(3):308-16.
    View in: PubMed
    Score: 0.310
  6. Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Psychopharmacology (Berl). 2008 May; 197(4):675-81.
    View in: PubMed
    Score: 0.303
  7. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry. 2006 Feb 01; 59(3):211-5.
    View in: PubMed
    Score: 0.256
  8. Benzodiazepines in clinical practice: consideration of their long-term use and alternative agents. J Clin Psychiatry. 2005; 66 Suppl 2:21-7.
    View in: PubMed
    Score: 0.245
  9. Internal cue exposure and the treatment of substance use disorders: lessons from the treatment of panic disorder. J Anxiety Disord. 2004; 18(1):69-87.
    View in: PubMed
    Score: 0.228
  10. Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone. J Clin Psychiatry. 1997; 58 Suppl 11:19-23.
    View in: PubMed
    Score: 0.140
  11. Innovative uses of benzodiazepines in psychiatry. Can J Psychiatry. 1993 Nov; 38 Suppl 4:S122-6.
    View in: PubMed
    Score: 0.113
  12. Long-term management of panic disorder. J Clin Psychiatry. 1990 May; 51 Suppl:11-3; discussion 50-3.
    View in: PubMed
    Score: 0.088
  13. Novel treatment approaches for refractory anxiety disorders. Depress Anxiety. 2008; 25(6):467-76.
    View in: PubMed
    Score: 0.075
  14. Augmentation treatment of psychotherapy for anxiety disorders with D-cycloserine. CNS Drug Rev. 2006 Fall-Winter; 12(3-4):208-17.
    View in: PubMed
    Score: 0.069
  15. Discussion: using benzodiazepines in clinical practice. J Clin Psychiatry. 2005; 66 Suppl 2:39-43; quiz 44-5.
    View in: PubMed
    Score: 0.061
  16. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol. 2004 Apr; 24(2):141-9.
    View in: PubMed
    Score: 0.058
  17. Personality and symptom sensitivity predictors of alprazolam withdrawal in panic disorder. Psychol Med. 2003 Apr; 33(3):511-8.
    View in: PubMed
    Score: 0.054
  18. Quality of life in social anxiety disorder compared with panic disorder and the general population. Psychiatr Serv. 2002 Jun; 53(6):714-8.
    View in: PubMed
    Score: 0.051
  19. Longitudinal outcome with pharmacotherapy in a naturalistic study of panic disorder. J Affect Disord. 2002 May; 69(1-3):201-8.
    View in: PubMed
    Score: 0.051
  20. Panic disorder and response to sertraline: the effect of previous treatment with benzodiazepines. J Clin Psychopharmacol. 2001 Feb; 21(1):104-7.
    View in: PubMed
    Score: 0.047
  21. Comorbidity, neurobiology, and pharmacotherapy of social anxiety disorder. J Clin Psychiatry. 2001; 62 Suppl 12:24-9.
    View in: PubMed
    Score: 0.046
  22. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol. 2000 Aug; 20(4):467-71.
    View in: PubMed
    Score: 0.045
  23. Group cognitive-behavior therapy for patients failing to respond to pharmacotherapy for panic disorder: a clinical case series. Behav Res Ther. 1999 Aug; 37(8):763-70.
    View in: PubMed
    Score: 0.042
  24. Clinical issues in the long-term treatment of panic disorder. J Clin Psychiatry. 1996; 57 Suppl 10:44-8; discussion 49-50.
    View in: PubMed
    Score: 0.033
  25. The longitudinal course and outcome of panic disorder. Psychiatr Clin North Am. 1995 Dec; 18(4):785-801.
    View in: PubMed
    Score: 0.033
  26. Integrated treatment of panic disorder. Bull Menninger Clin. 1995; 59(2 Suppl A):A4-26.
    View in: PubMed
    Score: 0.031
  27. Cognitive-behavioral therapy for benzodiazepine discontinuation in panic disorder patients. Psychopharmacol Bull. 1992; 28(2):123-30.
    View in: PubMed
    Score: 0.025
  28. Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder. CNS Spectr. 2008 Jun; 13(6):522-7.
    View in: PubMed
    Score: 0.019
  29. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry. 2005 Sep; 62(9):1022-30.
    View in: PubMed
    Score: 0.016
  30. Pharmacotherapy for bipolar disorder and comorbid conditions: baseline data from STEP-BD. J Clin Psychopharmacol. 2004 Oct; 24(5):512-20.
    View in: PubMed
    Score: 0.015
  31. Dizziness and panic disorder: a review of the association between vestibular dysfunction and anxiety. Ann Clin Psychiatry. 1998 Jun; 10(2):75-80.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.